- Home
- IONS vs NBIS Comparison
IONS vs NBIS Comparison
Compare IONS & NBIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- NBIS
- Stock Information
- Founded
- IONS 1989
- NBIS 2000
- Country
- IONS United States
- NBIS Netherlands
- Employees
- IONS N/A
- NBIS N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- NBIS
- Sector
- IONS Health Care
- NBIS
- Exchange
- IONS Nasdaq
- NBIS NYSE
- Market Cap
- IONS 4.6B
- NBIS 4.8B
- IPO Year
- IONS 1991
- NBIS 2011
- Fundamental
- Price
- IONS $32.26
- NBIS $28.27
- Analyst Decision
- IONS Buy
- NBIS Strong Buy
- Analyst Count
- IONS 18
- NBIS 3
- Target Price
- IONS $57.41
- NBIS $41.33
- AVG Volume (30 Days)
- IONS 1.7M
- NBIS 6.0M
- Earning Date
- IONS 04-30-2025
- NBIS 02-20-2025
- Dividend Yield
- IONS N/A
- NBIS N/A
- EPS Growth
- IONS N/A
- NBIS N/A
- EPS
- IONS N/A
- NBIS N/A
- Revenue
- IONS $717,253,000.00
- NBIS $117,500,000.00
- Revenue This Year
- IONS N/A
- NBIS $42,672.77
- Revenue Next Year
- IONS $27.39
- NBIS N/A
- P/E Ratio
- IONS N/A
- NBIS N/A
- Revenue Growth
- IONS N/A
- NBIS 462.20
- 52 Week Low
- IONS $23.95
- NBIS $14.09
- 52 Week High
- IONS $52.34
- NBIS $50.87
- Technical
- Relative Strength Index (RSI)
- IONS 57.55
- NBIS N/A
- Support Level
- IONS $31.66
- NBIS N/A
- Resistance Level
- IONS $33.98
- NBIS N/A
- Average True Range (ATR)
- IONS 1.30
- NBIS 0.00
- MACD
- IONS 0.41
- NBIS 0.00
- Stochastic Oscillator
- IONS 68.84
- NBIS 0.00
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About NBIS NEBIUS GROUP N V
Nebius Group NV is a tech company. It is a European provider of infrastructure and services to AI builders globally. The group builds full-stack infrastructure to service the growth of the AI industry, including the scale of GPU clusters, cloud platforms, tools, and services for developers. It has R&D hubs across Europe, North America and Israel.